ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC) [0.03%]
ALBAN（GETUG-AFU 37）：一项关于阿特朱单抗静脉给药联合卡介苗膀胱内灌注对比单纯使用卡介苗治疗高危、初治的非肌层浸润性膀胱癌患者的国际多中心 III 期开放标签随机试验
M Roupret,A Bertaut,G Pignot et al.
M Roupret et al.
Background: Standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT) is intravesical instillation with Bacillus Calmette-Guérin (BCG) (induction a...
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17) [0.03%]
帕博西尼联合来曲唑与每周一次紫杉醇，两者均联用曲妥珠单抗和帕捷特作为HR+/HER2+早期乳腺癌新辅助治疗：TOUCH试验（IBCSG 55-17）的初步结果
L Malorni,S Tyekucheva,A Gombos et al.
L Malorni et al.
Background: HR+/HER2+ breast cancer (BC) is a heterogeneous disease with low pathological complete response (pCR) to standard neoadjuvant treatment. CDK4/6 inhibitors with endocrine and anti-HER2 therapy have shown a pote...
Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173] [0.03%]
法国肉瘤组(GSF/GETO)进行的二期临床试验“对于局部晚期和转移性软骨肉瘤患者索拉非尼的效果评估”的勘误:[Ann Oncol 26 (2015) 2168-2173]
E Bompas,A Le Cesne,E Tresch-Bruneel et al.
E Bompas et al.
Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727] [0.03%]
"阿贝西利联合非甾体芳香化酶抑制剂作为HR+、HER2-晚期乳腺癌初始治疗的初始疗法：MONARCH 3研究最终总生存期结果的勘误"[Ann Oncol 2024; 35: 718-727]
M P Goetz,M Toi,J Huober et al.
M P Goetz et al.
Corrigendum to "Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population": [Ann Oncol 36 (2025) 520-528] [0.03%]
对“用于KRAS野生型局部晚期结直肠癌患者的新辅助FOLFOX联合和不联合帕尼单抗治疗：FOxTROT试验嵌入二期人群扩展生物标志物 panel结果的更正”[Ann Oncol 36 (2025) 520-528]
J F Seligmann,D Morton,F Elliott et al.
J F Seligmann et al.
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer [0.03%]
基于患者风险和偏好的个体化治疗：圣加仑国际乳腺癌共识2025年关于早期乳腺癌治疗的声明
H J Burstein,G Curigliano,M Gnant et al.
H J Burstein et al.
Background: Breast cancer is a global disease affecting millions of individuals. Ongoing advancements in multidisciplinary management of breast cancer patients warrant discussion and integration into standard treatment pl...
SUNNIFORECAST Trial Design Supported by Real-World Data in Papillary Renal Cell Carcinoma [0.03%]
SUNNIFORECAST试验设计基于透明细胞肾细胞癌的真实世界数据得到支持
Miguel Zugman,Jennifer R Rider,Diwyanshu Sahu et al.
Miguel Zugman et al.
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors [0.03%]
免疫检查点抑制剂、VEGF（R）抑制剂或多种靶向酪氨酸激酶抑制剂与放射治疗联合应用的安全性共识陈述（欧洲医学肿瘤学会和欧洲放射肿瘤学学会）
E S M van Aken,B Devnani,A Prelaj et al.
E S M van Aken et al.
Background: The combination of radiotherapy (RT) with targeted agents or immunotherapy may result in improved outcomes, but it can also increase toxicity. However, there is a paucity of high-quality toxicity data, leading...